A study to assess the effect of AZD5055 on the pharmacokinetics (PK) of Nintedanib in healthy participants.

Study identifier:D8960C00003

ClinicalTrials.gov identifier:NCT05644600

EudraCT identifier:2022-003116-84

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

An Open Label, Randomised Study in Healthy Participants to Investigate the Effect of AZD5055 on the Pharmacokinetics of Nintedanib.

Medical condition

Healthy subjects

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Nintedanib, AZD5055

Sex

All

Actual Enrollment

18

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 26 May 2023
Primary Completion Date: 17 Jul 2023
Study Completion Date: 17 Jul 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria